scholarly journals Role of Probiotics in the Management of COVID-19: A Computational Perspective

Nutrients ◽  
2022 ◽  
Vol 14 (2) ◽  
pp. 274
Author(s):  
Quang Vo Nguyen ◽  
Li Chuin Chong ◽  
Yan-Yan Hor ◽  
Lee-Ching Lew ◽  
Irfan A. Rather ◽  
...  
Keyword(s):  
Gut Microbiota ◽  
Research Finding ◽  
Adjunctive Treatment ◽  
Innate And Adaptive Immunity ◽  
Computational Approaches ◽  
Computational Perspective ◽  
Abundant Data ◽  
Gut Microbiota Dysbiosis

Coronavirus disease 2019 (COVID-19) was declared a pandemic at the beginning of 2020, causing millions of deaths worldwide. Millions of vaccine doses have been administered worldwide; however, outbreaks continue. Probiotics are known to restore a stable gut microbiota by regulating innate and adaptive immunity within the gut, demonstrating the possibility that they may be used to combat COVID-19 because of several pieces of evidence suggesting that COVID-19 has an adverse impact on gut microbiota dysbiosis. Thus, probiotics and their metabolites with known antiviral properties may be used as an adjunctive treatment to combat COVID-19. Several clinical trials have revealed the efficacy of probiotics and their metabolites in treating patients with SARS-CoV-2. However, its molecular mechanism has not been unraveled. The availability of abundant data resources and computational methods has significantly changed research finding molecular insights between probiotics and COVID-19. This review highlights computational approaches involving microbiome-based approaches and ensemble-driven docking approaches, as well as a case study proving the effects of probiotic metabolites on SARS-CoV-2.

Towards a disease-associated common trait of gut microbiota dysbiosis: The pivotal role of Akkermansia muciniphila

2020 ◽  
Vol 52 (9) ◽  
pp. 1002-1010 ◽  
Author(s):  
Loris Riccardo Lopetuso ◽  
Andrea Quagliariello ◽  
Mario Schiavoni ◽  
Valentina Petito ◽  
Alessandra Russo ◽  
...  
Keyword(s):  
Gut Microbiota ◽  
Pivotal Role ◽  
Akkermansia Muciniphila ◽  
Gut Microbiota Dysbiosis

scholarly journals Human Gut Microbiota in Health and Selected Cancers

2021 ◽  
Vol 22 (24) ◽  
pp. 13440
Author(s):  
Aleksandra Sędzikowska ◽  
Leszek Szablewski
Keyword(s):  
Gut Microbiota ◽  
Metabolic Diseases ◽  
Human Gut ◽  
Vast Number ◽  
Human Gut Microbiota ◽  
Internal And External Factors ◽  
Number Of Bacteria ◽  
Gut Microbiota Dysbiosis

The majority of the epithelial surfaces of our body, and the digestive tract, respiratory and urogenital systems, are colonized by a vast number of bacteria, archaea, fungi, protozoans, and viruses. These microbiota, particularly those of the intestines, play an important, beneficial role in digestion, metabolism, and the synthesis of vitamins. Their metabolites stimulate cytokine production by the human host, which are used against potential pathogens. The composition of the microbiota is influenced by several internal and external factors, including diet, age, disease, and lifestyle. Such changes, called dysbiosis, may be involved in the development of various conditions, such as metabolic diseases, including metabolic syndrome, type 2 diabetes mellitus, Hashimoto’s thyroidis and Graves’ disease; they can also play a role in nervous system disturbances, such as multiple sclerosis, Alzheimer’s disease, Parkinson’s disease, and depression. An association has also been found between gut microbiota dysbiosis and cancer. Our health is closely associated with the state of our microbiota, and their homeostasis. The aim of this review is to describe the associations between human gut microbiota and cancer, and examine the potential role of gut microbiota in anticancer therapy.

scholarly journals The role of probiotics and prebiotics in the proper functioning of gut microbiota and the treatment of diseases caused by gut microbiota dysbiosis

2020 ◽  
Vol 7 (1) ◽  
pp. 9-15
Author(s):  
Magdalena Frej-Mądrzak ◽  
Małgorzata Jeziorek ◽  
Jolanta Sarowska ◽  
Agnieszka Jama-Kmiecik ◽  
Irena Choroszy-Król
Keyword(s):  
Gut Microbiota ◽  
Proper Functioning ◽  
Gut Microbiota Dysbiosis

scholarly journals Gut Microbiota Profiles in Early- and Late-Onset Colorectal Cancer: A Potential Diagnostic Biomarker in the Future

Digestion ◽  
2021 ◽  
pp. 1-10
Author(s):  
Murdani Abdullah ◽  
Ninik Sukartini ◽  
Saskia Aziza Nursyirwan ◽  
Rabbinu Rangga Pribadi ◽  
Hasan Maulahela ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Risk Factors ◽  
Gut Microbiota ◽  
Late Onset ◽  
Diagnostic Biomarker ◽  
Incidence And Mortality ◽  
The Future ◽  
Early Onset Colorectal Cancer ◽  
Gut Microbiota Dysbiosis

<b><i>Background:</i></b> Researchers believe the role of gut microbiota dysbiosis in the raised incidence of early-onset colorectal cancer (EOCRC). The development of EOCRC may be associated with microbiota dysbiosis either dependently or independently (combined with other risk factors). <b><i>Summary:</i></b> Recently, the rising of incidence and mortality of EOCRC have been noted. Some researchers are looking for risk factors influencing this fact. They hypothesize that it may be because of microbiota dysbiosis. Microbiota dysbiosis has been known to promote cancer development through immunity dysregulation and chronic inflammation. Microbiomes profile in late-onset colorectal cancer (LOCRC) among older patients has been documented, but there is still lack of data about microbial profiles among younger colorectal cancer (CRC) patients. This review tries to explain microbial profiles differences between EOCRC and LOCRC as a potential diagnostic biomarker in the future, and whether microbiota can have a role in EOCRC genesis. <b><i>Key Messages:</i></b> Microbiota does vary with age, and EOCRC may be associated with colonization of some specific bacteria. Further studies about gut microbiota profiles in EOCRC and LOCRC may provide a new insight on diagnostic biomarker of CRC.

scholarly journals Food Preservatives Induce Proteobacteria Dysbiosis in Human-Microbiota Associated Nod2-Deficient Mice

2019 ◽  
Vol 7 (10) ◽  
pp. 383 ◽  
Author(s):  
Hrncirova ◽  
Machova ◽  
Trckova ◽  
Krejsek ◽  
Hrncir
Keyword(s):  
Gut Microbiota ◽  
Metabolic Diseases ◽  
Food Additives ◽  
Wild Type ◽  
Food Preservatives ◽  
Human Microbiota ◽  
Immune Mediated ◽  
Exposure Levels ◽  
Gut Microbiota Dysbiosis

: The worldwide incidence of many immune-mediated and metabolic diseases, initially affecting only the wealthy Western countries, is increasing rapidly. Many of these diseases are associated with the compositional and functional alterations of gut microbiota, i.e., dysbiosis. The most consistent markers of the dysbiosis are a decrease in microbiota diversity and an expansion of Proteobacteria. The role of food preservatives as potential triggers of gut microbiota dysbiosis has been long overlooked. Using a human microbiota-associated mouse model, we demonstrate that a mixture of common antimicrobial food additives induces dysbiosis characterised by an overgrowth of Proteobacteria phylum and a decrease in the Clostridiales order. Remarkably, human gut microbiota in a Nod2-deficient genetic background is even more susceptible to the induction of Proteobacteria dysbiosis by additives than the microbiota in a wild-type background. To conclude, our data demonstrate that antimicrobial food additives trigger gut microbiota dysbiosis in both wild-type and Nod2-deficient backgrounds and at the exposure levels reached in European populations. Whether this additive-modified gut microbiota plays a significant role in the pathogenesis of immune-mediated and metabolic diseases remains to be elucidated.

scholarly journals Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites

Gut ◽  
2020 ◽  
pp. gutjnl-2019-319664 ◽  
Author(s):  
Xiang Zhang ◽  
Olabisi Oluwabukola Coker ◽  
Eagle SH Chu ◽  
Kaili Fu ◽  
Harry C H Lau ◽  
...  
Keyword(s):  
Gut Microbiota ◽  
Fatty Liver ◽  
Dietary Cholesterol ◽  
Chow Diet ◽  
High Fat ◽  
Direct Role ◽  
Alcoholic Fatty Liver ◽  
Germ Free ◽  
Gut Microbiota Dysbiosis

ObjectiveNon-alcoholic fatty liver disease (NAFLD)-associated hepatocellular carcinoma (HCC) is an increasing healthcare burden worldwide. We examined the role of dietary cholesterol in driving NAFLD–HCC through modulating gut microbiota and its metabolites.DesignHigh-fat/high-cholesterol (HFHC), high-fat/low-cholesterol or normal chow diet was fed to C57BL/6 male littermates for 14 months. Cholesterol-lowering drug atorvastatin was administered to HFHC-fed mice. Germ-free mice were transplanted with stools from mice fed different diets to determine the direct role of cholesterol modulated-microbiota in NAFLD–HCC. Gut microbiota was analysed by 16S rRNA sequencing and serum metabolites by liquid chromatography–mass spectrometry (LC–MS) metabolomic analysis. Faecal microbial compositions were examined in 59 hypercholesterolemia patients and 39 healthy controls.ResultsHigh dietary cholesterol led to the sequential progression of steatosis, steatohepatitis, fibrosis and eventually HCC in mice, concomitant with insulin resistance. Cholesterol-induced NAFLD–HCC formation was associated with gut microbiota dysbiosis. The microbiota composition clustered distinctly along stages of steatosis, steatohepatitis and HCC. Mucispirillum, Desulfovibrio, Anaerotruncus and Desulfovibrionaceae increased sequentially; while Bifidobacterium and Bacteroides were depleted in HFHC-fed mice, which was corroborated in human hypercholesteremia patients. Dietary cholesterol induced gut bacterial metabolites alteration including increased taurocholic acid and decreased 3-indolepropionic acid. Germ-free mice gavaged with stools from mice fed HFHC manifested hepatic lipid accumulation, inflammation and cell proliferation. Moreover, atorvastatin restored cholesterol-induced gut microbiota dysbiosis and completely prevented NAFLD–HCC development.ConclusionsDietary cholesterol drives NAFLD–HCC formation by inducing alteration of gut microbiota and metabolites in mice. Cholesterol inhibitory therapy and gut microbiota manipulation may be effective strategies for NAFLD–HCC prevention.

scholarly journals Gut Microbiota: Novel Therapeutic Target of Ginsenosides for the Treatment of Obesity and Its Complications

2021 ◽  
Vol 12 ◽  
Author(s):  
Tongxi Zhuang ◽  
Wei Li ◽  
Li Yang ◽  
Zhengtao Wang ◽  
Lili Ding ◽  
...  
Keyword(s):  
Gut Microbiota ◽  
Medical Intervention ◽  
Metabolic Effects ◽  
Clinical Settings ◽  
Treatment Of Obesity ◽  
Endogenous Metabolites ◽  
Endogenous Substances ◽  
Gut Microbiota Dysbiosis

Obesity, generally characterized by excessive lipid accumulation, is a metabolic threat worldwide due to its rapid growth in global prevalence. Ginsenosides are crucial components derived from natural plants that can confer metabolic benefits for obese patients. Considering the low bioavailability and degradable properties of ginsenosides in vivo, it should be admitted that the mechanism of ginsenosides on anti-obesity contribution is still obscure. Recently, studies have indicated that ginsenoside intervention has beneficial metabolic effects on obesity and its complications because it allows for the correction of gut microbiota dysbiosis and regulates the secretion of related endogenous metabolites. In this review, we summarize the role of gut microbiota in the pathogenetic process of obesity, and explore the mechanism of ginsenosides for ameliorating obesity, which can modulate the composition of gut microbiota by improving the metabolism of intestinal endogenous substances and alleviating the level of inflammation. Ginsenosides are expected to become a promising anti-obesity medical intervention in the foreseeable clinical settings.

scholarly journals Taxonomical and functional changes in COVID-19 faecal microbiome are related to SARS-CoV-2 faecal load

2021 ◽  
Author(s):  
Jean Armengaud ◽  
Lucia Grenga ◽  
Olivier Pible ◽  
Guylaine Miotello ◽  
Karen Culotta ◽  
...  
Keyword(s):  
Gut Microbiota ◽  
Exploratory Study ◽  
Therapeutic Strategies ◽  
Intestinal Infection ◽  
Gi Tract ◽  
Functional Changes ◽  
Gi Symptoms ◽  
Faecal Microbiome ◽  
Gut Microbiota Dysbiosis

Abstract Since the beginning of the pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) the gastro-intestinal (GI) tract has emerged as an important organ influencing the propensity to and potentially severity of the related COVID-19 disease. However, the contribution of the SARS-CoV-2 intestinal infection on COVID-19 pathogenesis remains to be clarified. In this exploratory study, we evidenced that alterations in the composition of the gut microbiota depends on the levels of SARS-CoV-2 RNA in the gastrointestinal tract but not on the presence of SARS-CoV-2 in the respiratory tract, COVID-19 severity and GI symptoms. Altered molecular functions in the microbiota profiles of high SARS-CoV-2 RNA level faeces as established by metaproteomics highlight mechanisms that may contribute to vicious cycles. Uncovering the role of this gut microbiota dysbiosis could drive the investigation of alternative therapeutic strategies to favour the clearance of the virus and potentially mitigate the effect of SARS-CoV-2 infection.

scholarly journals Gut Microbiota and Obesity: A Role for Probiotics

Nutrients ◽  
2019 ◽  
Vol 11 (11) ◽  
pp. 2690 ◽  
Author(s):  
Ludovico Abenavoli ◽  
Emidio Scarpellini ◽  
Carmela Colica ◽  
Luigi Boccuto ◽  
Bahare Salehi ◽  
...  
Keyword(s):  
Gut Microbiota ◽  
Current Knowledge ◽  
Obese Patients ◽  
Bacterial Strains ◽  
Literature Searching ◽  
Human Gut ◽  
Unhealthy Lifestyle ◽  
Metabolic Functions ◽  
Gut Microbiota Dysbiosis

Nowadays, obesity is one of the most prevalent human health problems. Research from the last 30 years has clarified the role of the imbalance between energy intake and expenditure, unhealthy lifestyle, and genetic variability in the development of obesity. More recently, the composition and metabolic functions of gut microbiota have been proposed as being able to affect obesity development. Here, we will report the current knowledge on the definition, composition, and functions of intestinal microbiota. We have performed an extensive review of the literature, searching for the following keywords: metabolism, gut microbiota, dysbiosis, obesity. There is evidence for the association between gut bacteria and obesity both in infancy and in adults. There are several genetic, metabolic, and inflammatory pathophysiological mechanisms involved in the interplay between gut microbes and obesity. Microbial changes in the human gut can be considered a factor involved in obesity development in humans. The modulation of the bacterial strains in the digestive tract can help to reshape the metabolic profile in the human obese host as suggested by several data from animal and human studies. Thus, a deep revision of the evidence pertaining to the use probiotics, prebiotics, and antibiotics in obese patients is conceivable

Sign in / Sign up

Export Citation Format

Share Document